Drug Approval | January 14, 2022
WHO recommends two new drugs for COVID-19
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
Flattish volume growth and subdued new launches were key factors for last month
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
The medicine is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harbouring alterations leading to METex14 skipping
Subscribe To Our Newsletter & Stay Updated
